We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Agent Delays Pre-term Labor in Rats

By HospiMedica staff writers
Posted on 29 Aug 2005
A clinical trial has shown that mixed oxytocin (OT)-vasopressin receptor antagonist atosiban exhibited similar efficacy as betablockers in treating pre-term labor in rats, but with markedly lower maternal cardiovascular side effects.

A long-time aim of obstetrical research has been to find agents that could delay or diminish pre-term labor because it is a leading cause of infant mortality and morbidity. More...
In the United States, disorders associated with short gestation and low birth weight accounted for 4,400 or 15.7% of infant deaths in 2002, second only to congenital disorders, which accounted for 5,570 deaths.

There is evidence that OT plays an important role in pre-term labor, especially causing contractions of the myometrial muscles. OT-receptor agonists have been shown to inhibit spontaneous myometrial contractions in vitro and to suppress myometrial activity in live animal models.

"Delaying labor with oxytocin receptor antagonist may significantly reduce infant morbidiy, including lung disease, intraventricular hemorrhage, and possibly even death,” said David P. Brooks, vice president, biology, U.S., GlaxoSmithKline Pharmaceuticals, (GSK, London, UK; www.gsk.com). He explained that GSK researchers have developed a series of nonpeptide selective oxytocin receptor antagonists that have a high affinity for the human and rat OT receptors with a greater than 1,000-fold selectivity over the human
vasopressin receptors. "These compounds suppress spontaneous contractions in late-term (19-21 days) pregnant rats,” he added.






Related Links:
GlaxoSmithKline Pharma

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.